Bicara Therapeutics Inc. (BCAX) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Bicara Therapeutics Inc. (NASDAQ: BCAX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $9.73 (-0.31% 1D, market cap $643.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BCAX ranks #478 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BCAX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OLMA (Olema Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -32.8%, cap $641.4M) and ABUS (Arbutus Biopharma Corporation) posts a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $656.0M). Among the 5-stock peer group, BCAX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
Per BCAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002023658), Bicara Therapeutics Inc. generated $0 in revenue, -$137.9M in net income, and -$107.1M in free cash flow against $431.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 17.5 (OVERSOLD (<32))
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While BCAX currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.74) and Max Pain ($10.22) forces dealer call-delta covering toward $32.54.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Bicara Therapeutics Inc. (BCAX) slipped -0.31% to $9.73, trading at 6% of its 52-week range ($8.36 – $30.99). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Goldman Sachs analyst Richard Law downgrades Bicara Therapeutics (NASDAQ:BCAX) from Neutral to Sell and lowers the price target from $20 to $8.
Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and lowers the price target from $33 to $24.
Today's US session featured double-digit moves, with KPTI up 59.38% and JDZG down 77.87% among the largest percentage swings.
Today's US market movers: top gainers and decliners ranked by percentage change, with double-digit moves on both sides.
Oct. 28 gap movers: POM, BRAI, BOOM, LUNG and AXGN were among notable gap-up stocks, while BCAX, HUHU, SCKT, MKDW and MEGL posted steep gap-down declines.
Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out yesterday.
BTIG analyst Jeet Mukherjee reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Buy and maintains $39 price target.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BCAX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BCAX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Bicara Therapeutics Inc. (BCAX) ranks #478 by composite RQD confidence (45/100, grade D) and #413 by equity capitalization ($643.9M). Within this direct 5-issuer industry benchmark cohort, BCAX leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. BCAX currently leads its immediate peer cohort in composite quantitative strength at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BCAX
ACTIVE
Bicara Therapeutics Inc. | D | 45/100 | — | — | -35.0% | -0.31% | $643.9M | Benchmark Subject |
| OLMA Olema Pharmaceuticals Inc. | E | 33/100 | — | — | -32.8% | -2.14% | $641.4M | /olma-vs-bcax → |
| ABUS Arbutus Biopharma Corporation | E | 22/100 | — | — | -35.0% | -0.93% | $656.0M | /abus-vs-bcax → |
| LXRX Lexicon Pharmaceuticals Inc. | D- | 39/100 | — | 96.0% | -31.5% | -0.34% | $658.5M | /lxrx-vs-bcax → |
| IMMX Immix Biopharma Inc. | E | 33/100 | — | — | -35.0% | -1.78% | $661.6M | /immx-vs-bcax → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bicara Therapeutics Inc. (BCAX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$137.9M, operating cash flow of -$106.8M, and free cash flow of -$107.1M (-43.2% YoY). On the balance sheet, BCAX closed FY2025 with $431.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$137.9M | -$106.8M | -$107.1M | $431.0M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$68.0M | -$74.8M | -$74.8M | $510.0M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$52.0M | -$45.6M | -$45.6M | — | — |
As of 2026-11-01, Bicara Therapeutics Inc. (NASDAQ: BCAX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $9.73 (-0.31% 1D, market cap $643.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BCAX ranks #478 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BCAX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OLMA (Olema Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -32.8%, cap $641.4M) and ABUS (Arbutus Biopharma Corporation) posts a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $656.0M). Among the 5-stock peer group, BCAX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
Per BCAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002023658), Bicara Therapeutics Inc. generated $0 in revenue, -$137.9M in net income, and -$107.1M in free cash flow against $431.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
BCAX last traded at $9.73 (-0.31% on volume of 3,197,807 shares), positioning the stock -50.71% below its 50-day simple moving average ($19.74) and -54.13% below its 200-day simple moving average ($21.21). Across its 52-week range of $8.36 to $30.99, BCAX sits at the 6.1% percentile with a 14-day RSI of 17.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($8.51 to $10.95).
Why BCAX Stock slipped -0.31% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).